Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations (Tables)

v3.21.2
Discontinued Operations (Tables)
6 Months Ended
Jun. 30, 2021
Discontinued Operations  
Schedule of components of loss from discontinued operations as reported in our statements of operations and comprehensive loss and assets and liabilities reported as discontinued operations in our condensed balance sheets

​

​

​

​

​

​

​

​

​

    

Three Months Ended

​

Six Months Ended

​

​

June 30, 2020

​

June 30, 2020

​

 

(In thousands, except per share data)

Revenue:

 

​

  

​

​

​

Product revenue

​

$

76

​

$

286

​

​

​

​

​

​

​

Costs and expenses:

​

 

  

​

 

​

Cost of goods sold

​

 

228

​

 

399

Research and development

​

 

363

​

 

828

Selling, general and administrative

​

 

2,251

​

 

4,077

Total costs and expenses

​

 

2,842

​

 

5,304

Loss from discontinued operations

​

 

(2,766)

​

 

(5,018)

Other expense, net

​

 

—

​

 

—

Net loss from discontinued operations

​

$

(2,766)

​

$

(5,018)

Basic and diluted net loss per common share from discontinued operations

​

$

(0.87)

​

$

(1.70)

Weighted average shares used in computing basic and diluted net loss per common share

​

 

3,165

​

 

2,960

​

​

​

​

​

​

​

​

​

​

June 30, 

    

December 31,

​

    

2021

    

2020

(In thousands)

​

​

  

 

​

  

Prepaid expenses and other current assets

​

$

70

​

$

181

Discontinued operations – current assets

​

$

70

​

$

181

​

​

​

​

​

​

​

Accounts payable

​

$

1,249

​

$

1,515

Accrued clinical trials expenses

​

 

25

​

 

80

Accrued sales allowances

​

 

—

​

 

61

Other accrued liabilities

​

 

353

​

 

304

Discontinued operations – current liabilities

​

$

1,627

​

$

1,960